LNG Emissions Could Fall 60% With $100 Billion Invest
The International Energy Agency said LNG emissions could be slashed by over 60% using today's technologyif investors pony up roughly $100 billion, the agency's latest report shows.
The IEA pegs annual greenhouse gases from the global liquefied natural gas supply chain at about 350 million tonnes of CO?-equivalent and estimates $100 billion in upfront capital would fund electrification, methane-leak mitigation and CCUS across all viable LNG facilities.
Roughly 70% of those emissions come from CO? released during combustion or venting, while the remaining 30% stems from unburnt methane slipping into the atmosphere.
Despite cleaner life-cycle footprintsmore than 99% of LNG consumed in 2024 emits less than coal and on average yields about 25% lower emissionsthe IEA warns that comparing LNG only to coal sets the bar too low given broader decarbonization opportunities.
Beyond electrification and CCUS, boosting process efficiency and deploying carbon capture at liquefaction plants could drive down both CO? and methane output. Major LNG producers like Shell (NYSE:SHEL), ExxonMobil (NYSE:XOM), TotalEnergies (NYSE:TTE) and Chevron (NYSE:CVX) are positioned to benefit from, or be challenged by, the shift toward cleaner operations.
Why it matters: Energy investors need to weigh potential returns from financing clean-tech upgrades against regulatory pressure and emerging carbon-pricing regimes that could penalize high-emission producers.
Closing: Markets will be watching next month's shareholder meetings at SHEL, XOM and CVX for any new clean-energy commitments or capital-allocation shifts to back the IEA's $100 billion roadmap.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Retail Traders Just Sent This AI Health Stock Soaring 60%
Oscar Health (NYSE:OSCR) has exploded nearly 60% this week, adding close to $2 billion in market cap without a single press release or earnings update. The real catalyst? A retail trading frenzy. OSCR became one of the most-mentioned names on r/WallStreetBets, and trading volume followed suitnearly 50 million shares changed hands on Wednesday alone, the second-highest in the company's history. Options activity lit up as well, with call volumes hitting a record 152,414 that day, and another 95,000 contracts moving by Friday morning, nearly triple the norm. Beneath the surge is a company with serious revenue momentumup 48% in 2023 and 57% in 2024. Adjusted earnings per share reached $0.92 in Q1 2025. But Oscar isn't just selling insuranceit's selling a story. Management brands the company as a health-tech platform, powered by AI and run on what it calls a continuous hackathon model. That pitch, familiar to anyone who's followed high-multiple tech names, is likely helping Oscar catch a more generous valuation than traditional insurers. Retail traders appear to be buying into that promise. Another factor? The Kushner connection. Joshua Kushner, vice chairman of Oscar's board and brother to Jared Kushner, has remained a prominent name in business and politics alike. That visibility might be adding an extra layer of speculation to the mix. But for now, the stock's movement is being driven more by momentum than fundamentals. Oscar is just $3 shy of its all-time highand the retail crowd seems determined to carry it the rest of the way. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
HSBC Downgrades Chevron (CVX) to Hold, Lowers PT
Chevron Corporation (NYSE:CVX) is one of the 10 Best Oil and Gas Stocks to Buy Now. On May 13, HSBC analysts downgraded Chevron Corporation (NYSE:CVX) from a 'Buy' to a 'Hold' rating and reduced the price target from $176 to $158. This decision came after the company announced it would reduce its share buyback program when it released its first-quarter earnings. A tanker truck making its way through a refinery facility. . Chevron Corporation's (NYSE:CVX) Chief Financial Officer, Eimear Bonner, said that the company's share repurchases for 2025 might be between $11.5 billion and $13 billion, which would be in the lower end of the company's guidance of $10 billion to $20 billion. HSBC analysts pointed out that Chevron Corporation (NYSE:CVX) no longer trades on par with its European competitors in terms of total distribution yield. This change came after the cut in buybacks. The analysts also noted that Chevron Corporation (NYSE:CVX) is currently trading at a 12-13% discount to Exxon based on expected 2025-26 price-to-cash flow ratios. HSBC analysts believe that this discount is fair given the higher risks associated with Chevron Corporation (NYSE:CVX). Chevron Corporation (NYSE:CVX) is one of the world's largest energy corporations. The company produces crude oil and natural gas. While we acknowledge the potential of CVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None.
Yahoo
an hour ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
